PhaseV, a leader in AI/ML-driven clinical development, has announced significant advancements in its platform designed to transform how pharmaceutical and biotech companies approach clinical trials. The company will demonstrate these new capabilities at several upcoming industry events, beginning with the Chief Medical Officer (CMO) Summit 360° in Boston this April.
The newly unveiled tools enable clinical development teams to seamlessly integrate learnings from previous trials into the design of future studies—bridging two processes that have traditionally been conducted separately. This integration represents a significant step forward in applying artificial intelligence to the complex challenges of drug development.
"For the first time, clinical teams can leverage causal ML-driven insights from prior trials and real-world data to inform the design of future trials - all within a single, end-to-end multi-modal platform," said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. "This approach enables real-time evaluation of various parameters and their impact in order to increase the probability of success."
Key Platform Capabilities
PhaseV's platform features two groundbreaking capabilities that address critical challenges in clinical development:
The Causal to Adaptive capability integrates real-world and clinical trial data to improve planning, efficiency, and decision-making for future clinical trials. By applying causal machine learning principles, the system can identify relationships between variables that might otherwise remain hidden in complex datasets.
The Clinical Trial Success Prediction tool enables trial sponsors to quantify the probability of success by analyzing historical trial data, trial parameters, and real-world evidence. The system generates a probability score that supports more informed decision-making, potentially reducing the high failure rates that plague pharmaceutical development.
"Integrating causal ML and AI capabilities with Bayesian adaptive tools is unique and significantly more advanced than existing solutions currently available on the market," explained Brad Carlin, PhD, Senior Director of Data Science and Statistics at PhaseV. "Our platform is a true game-changer for the industry."
Demonstrated Impact on Clinical Development
According to company data, PhaseV's platform has already delivered impressive results for its clients, including:
- Reduction in trial costs by up to 25%
- Decrease in enrollment size and trial duration by up to 40%
- Increase in the probability of trial success by up to 30%
These metrics represent significant improvements in an industry where clinical trials regularly face delays, cost overruns, and high failure rates. The platform's ability to optimize trial design and execution could accelerate the development of new treatments across multiple therapeutic areas.
Expanding Scientific Presence
Following the CMO Summit in Boston, PhaseV will present its technology at several scientific conferences throughout 2025, including:
- IBD Innovate 2025 (April 9-10, New York, NY)
- Duke Industry Statistics Symposium 2025 (April 9-11, Durham, NC)
- Joint Statistical Meetings (JSM) 2025 (August 2-7, Nashville, TN)
- 13th International Conference on Multiple Comparison Procedures (August 12-15, Philadelphia, PA)
At these events, PhaseV's leadership and scientific team will present on topics including causal machine learning for estimating uncertainty, practical challenges in designing adaptive clinical trials, and innovative statistical methods for robust analysis from small samples.
The company's representatives will also attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30th to June 2nd, highlighting the platform's applications in oncology clinical development.
Therapeutic Applications
PhaseV's technology has been applied across multiple therapeutic areas, including neurology, oncology, immunology, gastroenterology, and rare diseases. This broad applicability demonstrates the platform's flexibility in addressing diverse clinical development challenges.
The company's focus on inflammatory bowel disease, as evidenced by its participation in IBD Innovate 2025, suggests particular success in this therapeutic area, where clinical trials often face challenges related to patient heterogeneity and complex endpoints.
"As clinical development becomes increasingly complex, integrating AI and advanced statistical modeling is essential to optimize efficiency and deliver results," noted Pryluk. "We're excited to showcase how our rigorous scientific approach, unparalleled data assets, and novel use of real-world evidence are reshaping trial design, analysis and execution."
Industry Adoption
Since its founding, PhaseV has built an impressive client base, with its platform being adopted by more than 30 global pharmaceutical and biotech companies. This rapid adoption suggests that the industry recognizes the potential value of AI-driven approaches to clinical development.
The company's focus on rigorous statistical methods and regulatory compliance likely contributes to this success, as pharmaceutical companies must balance innovation with adherence to established scientific and regulatory standards.
As the industry continues to seek ways to improve the efficiency and success rates of clinical trials, PhaseV's AI-powered platform represents a promising approach to addressing these persistent challenges in drug development.
